Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 29Myeloid 18Classical hematology 3Thoracic 2Lymphoid 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Genitourinary 1Endocrine 1CNS 1Breast 1

Conditions

Myeloproliferative Disorders 2Anemia, Refractory, with Excess of Blasts 2Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Cytopenia 1

Interventions

Cyclophosphamide 24fludarabine phosphate 18Whole-Body Irradiation 17fludarabine 16Mycophenolic Acid 16Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Busulfan 12Melphalan 11apixaban 10Biopsy 7Rivaroxaban 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Filgrastim 5Cyclosporine 5Azacitidine 5thymoglobulin 4X-Rays 4Sirolimus 4Rituximab 4Injections 4Enoxaparin 4Decitabine 4Bone Marrow Transplantation 4Aspirin 4Antilymphocyte Serum 4venetoclax 3pegylated granulocyte colony-stimulating factor 3hetrombopag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
decitabine and cedazuridine drug combination × Classical hematology × 1 year × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT06802146 2026-04-23

Early Intervention in High Risk CCUS

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Recruiting
108 enrolled
Classical hematology

Cytopenia

NCT06284460 2026-02-13

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Classical hematologyMyeloid

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡